The 211At-labeled anti-CD38 showed therapeutic advantages in a disseminated MM disease model [115], while daratumumab labeled with 225Ac or 177Lu was tested in a preclinical model of disseminated MM, with 225Ac demonstrating superior cytotoxicity [116]. This evidence concerns the gene CD38 and Miyoshi myopathy.